DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study of Coagulation Activation Markers and Pre Eclampsia

Information source: University Hospital, Lille
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pre Eclampsia

Phase: N/A

Status: Completed

Sponsored by: University Hospital, Lille

Official(s) and/or principal investigator(s):
VĂ©ronique Houfflin Debarge, PHD, Principal Investigator, Affiliation: Universituy Hospital Of Lille, France


The primary purpose of the trial is to evaluate coagulation activator markers in patients with pre eclampsia compared to control (normal pregnancy) and to correlate these markers with the severity of the pathology.

Clinical Details

Official title: Coagulation Activation Markers and Pre Eclampsia : Correlation With Complications

Study design: Observational Model: Case Control, Time Perspective: Prospective

Primary outcome: Endogenous thrombin potential

Secondary outcome:

genotype-phenotype correlation (Polymorphism of prostacyclin-synthetase promoter CYP8A1

In preeclampsia group : correlation between biological markers and severity of the disease

evolution of endogenous thrombin potential in women with preeclampsia

Detailed description: 100 pre-eclamptic patients will be compared to 200 control patients (100 control matched on gestational age at inclusion and 100 control matched on delivery mode (section). Blood and urine samples will be collected at PE diagnosis, delivery and post partum. Two axes will be considered: 1. Thrombography, or kinetic measurement of thrombin generation, by studying the coagulant profile according to Hemker's method in CAT System (Calibrated Automated Thrombogram) and by thromboelastogram in ROTEM technique (delocalized coagulation analyzer), in parallel to specific activation markers (thrombin-antithrombin complex, fibrin monomers). 2. The balance of prostacyclin/thromboxane A2 by using ELISA method for urine samples and genotype-phenotype correlation (Polymorphism of prostacyclin-synthetase's promoter CYP8A1).


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Female.


Inclusion Criteria:

- 18 years old

- diagnosis of pre eclampsia

Exclusion Criteria:

- multiple pregnancy

- less than 18 year old

Locations and Contacts

University Hospital of Lille, Lille, Nord 59037, France
Additional Information

Starting date: May 2010
Last updated: December 17, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017